Semin Thromb Hemost 2008; 34(3): 282-285
DOI: 10.1055/s-0028-1082272
© Thieme Medical Publishers

Antiphospholipid Antibodies and Antiphospholipid Syndrome in Patients with Malignancies: Features, Incidence, Identification, and Treatment

Wolfgang Miesbach1
  • 1Medical Clinic III, Institute of Transfusion Medicine, University Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany
Further Information

Publication History

Publication Date:
21 August 2008 (online)

Preview

ABSTRACT

Thrombotic events associated with antiphospholipid (aPL) antibodies can be the first manifestation of malignancy. The pathologic significance of aPL antibodies in patients with malignancies, however, is still unclear. It remains an unresolved issue as to whether the presence of aPL antibodies may be considered as an “epiphenomenon” of the malignancy itself or whether it contributes directly to the development of thrombosis in these patients.

In particular, solid tumors may be associated with the development of aPL antibodies, enhancing the thrombophilic risk in these patients. In general, routine anticoagulant prophylaxis with low-molecular-weight heparin in cancer patients with positive aPL antibodies is strongly indicated.

REFERENCES

Wolfgang MiesbachM.D. 

Medical Clinic III, Institute of Transfusion Medicine, Johann Wolfgang Goethe University

Frankfurt/Main, Department of Medicine III, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany

Email: wolfgang.miesbach@kgu.de